Coffee and Metabolic Health Outcomes

Insulin Resistance Clinical Trial

— COMETH  

Official title:

Influence of Coffee Consumption on Insulin Sensitivity in Overweight and Insulin Resistant Subjects.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01738399
• Other study ID #: 11.09.NRC
• Status: Completed
• Phase: N/A
• First received: November 28, 2012
• Last updated: April 21, 2015
• Start date: April 2012
• Est. completion date: December 2014

Study information

• Verified date: March 2012
• Source: National University Hospital, Singapore
• Contact: n/a
• Is FDA regulated: No
• Health authority: Singapore: Domain Specific Review Boards
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to investigate the long-term (24 weeks) effects of coffee consumption on insulin sensitivity in insulin resistant individuals.

Description:

Coffee is a major source of the phenolic acid chlorogenic acid and a substantial source of trigonelline, niacin, lignans magnesium, and potassium. Several of these compounds have been shown to improve glucose metabolism in animal models. Consumption of coffee was inversely associated with the risk of type-2 diabetes in prospective cohort studies across the world. Consumption of 3 to 4 cups of coffee per day was associated with an approximately 25% lower risk of type-2 diabetes. However, direct evidence of the efficacy of coffee to reduce blood glucose and insulin resistance parameters in humans from randomized trials is still lacking. In recent small trials of short duration (up to 6 weeks) coffee consumption increased levels of the insulin-sensitizing hormone adiponectin, but did not significantly improve insulin sensitivity These results suggest that a larger longer-term trial of the effects of coffee consumption on directly measured insulin sensitivity is warranted.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 128
• Est. completion date: December 2014
• Est. primary completion date: December 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 35 Years to 69 Years

Eligibility

Inclusion Criteria:

• Subjects classified as being insulin-resistant in the screening visit. Subjects should have a non-diabetic fasting plasma glucose concentration (< 7.0 mM) and a HOMA-IR > 2.2. The HOMA-IR was demonstrated as a reliable indicator of insulin resistance strongly correlated with values obtained by clamp (4). The cut-off value of the HOMA-IR was defined according to data obtained in the Singapore cohort. It corresponds to the 75th percentile of the population. The HOMA-IR cut-off was subsequently revised to = 1.3 to increase recruitment rates.

• Age: = 35 to = 69 years old

• Body mass index : = 22.5 to = 35.4 kg/m2

• Users of at least 1 cups of caffeinated coffee per day who are willing to be randomized to any of the interventions.

• Subjects should be willing to stop consuming caffeinated soft drinks or supplements during the study and to drink coffee with non-dairy creamer.

• Non-smokers (< 1 cigarette per week)

• Participants have been weight stable for at least -8 weeks pre-ceding the screening visit (± 2.5 kgs).

• Chinese, Malay and Indian ethnicity

Exclusion Criteria:

Subjects representing one or more of the following criteria are excluded from participation in the study:

• Any condition/illness that may affect the study outcomes or would make participation potentially harmful such as pregnancy or breastfeeding, diabetes mellitus, heart disease, stroke, hypertension, malabsorption syndromes, GERD, a history of ulcer, clotting or bleeding disorders,allergy to the test beverage, allergy to insulin, according to a detailed medical history.

• Participants who are allergic to foods may be excluded based on the investigator's discretion.

• Participants consume > 2 alcoholic servings/day on a regular basis and > 8 caffeinated servings (based on tea and coffee)/day

• Present drug abuse or use of medications that could interfere with the treatment including bronchodilators, quinolone antibiotics, monoamine oxidase inhibitors, anxiolytics, ranitidine, corticosteroids, growth hormone, anti-hypertensives. These conditions will be screened based on subject reporting. Participants will be asked to bring in their current medications at the time of screening, and these will be checked by the study-staff.

• Subject is taking traditional medications, herbal or dietary supplements that may affect the study outcome in the opinion of the investigators.

• Subject who cannot be expected to comply with the study procedures in the opinion of the investigators.

• Currently participating or having participated in another clinical trial during the last 12 weeks prior to the beginning of this study.

• Premenopausal women with self-reported irregular menstrual cycles or peri-menopausal women (participants who stopped getting their menses for less than 48 weeks ).

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Insulin Resistance

Intervention

Dietary Supplement:
• Coffee

• Placebo

Locations

Country	Name	City	State
Singapore	Saw Swee Hock School of Public Health	Singapore

Sponsors (2)

Lead Sponsor	Collaborator
National University Hospital, Singapore	Nestlé

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in insulin sensitivity when compared to baseline as measured using the euglycemic hyperinsulinemic clamp.		Baseline and 24 weeks	No
Secondary	Change in fasting plasma glucose concentration from baseline to 12 weeks		Baseline, 12 weeks	No
Secondary	Change in fasting plasma glucose concentration from baseline to 24 weeks		Baseline, 24 weeks	No
Secondary	Change in fasting plasma total adiponectin concentrations from baseline to 12 weeks		Baseline, 12 weeks	No
Secondary	Change in fasting plasma total adiponectin concentrations from baseline to 24 weeks		Baseline, 24 weeks	No